RANBAXY

Ranbaxy Laboratories Limited has informed the Exchange regarding a Press Release dated May 10, 2011 titled "Ranbaxy continues to improve performance across developed and emerging markets - Sales $474 Mn, EBITDA $95 Mn, PAT $67 Mn".

Ranbaxy Laboratories Limited has informed the Exchange regarding the consolidated Results for the quarter ended on 31-MAR-2011 as follows: Net Sales of Rs. 214302 lacs for quarter ending on 31-MAR-2011 against Rs. 248674.9 lacs for the quarter ending on 31-MAR-2010. Net Profit / (Loss) of Rs. 30438.7 lacs for the quarter ending on 31-MAR-2011 against Rs. 96058.4 lacs for the quarter ending on 31-MAR-2010.

Ranbaxy Laboratories Limited has informed the Exchange regarding the standalone Results for the quarter ended on 31-MAR-2011 as follows: Net Sales of Rs. 105644.4 lacs for quarter ending on 31-MAR-2011 against Rs. 164851.4 lacs for the quarter ending on 31-MAR-2010. Net Profit / (Loss) of Rs. (5290.7) lacs for the quarter ending on 31-MAR-2011 against Rs. 87180.2 lacs for the quarter ending on 31-MAR-2010.

Ranbaxy Laboratories Limited has submitted to the Exchange the Standalone and Consolidated Financial Results for the period ended March 31,2011.

Ranbaxy Laboratories Limited has submitted to the Exchange a copy of the proceedings of the Annual General Meeting of the Company held on May 09, 2011.

Ranbaxy Laboratories Limited has submitted to the Exchange a copy of the notice of the Annual General Meeting of the company to be held on May 09, 2011.

Ranbaxy Laboratories Limited has informed the Exchange that the ESOPs Allotment Committee of Directors vide Resolution by Circulation passed on April 11,2011 allotted 110,922 Equity Shares on exercise of stock options under the Employees Stock Option Scheme(s) of the Company. The paid-up Equity Share Capital of the Company post allotment is 421,363,230 Equity Shares of Rs. 5 each aggregating Rs. 2,106,816,150/-.

Ranbaxy Laboratories Limited has informed the Exchange that the Company has fully redeemed US$440,000,000 Zero Coupon Convertible Bonds ("Bonds") on March 18, 2011 (being the maturity date of the Bonds).

Ranbaxy Laboratories Limited has informed the Exchange regarding a press release dated March 01, 2011, titled "Daiichi Sankyo to Leverage Ranbaxy's Network to Market Its Innovative Products in Singapore".

Ranbaxy Laboratories Limited has informed the Exchange that at the meeting of Board of Directors held on February 22, 2011: (1) Annual General Meeting (AGM) of the Company has been fixed for May 09, 2011. (2) Share Transfer books for the purpose of dividend will remain closed from April 30, 2011 to May 09, 2011 (both days inclusive).

Ranbaxy Laboratories Limited has informed the Exchange regarding a press release dated February 22, 2011, titled "RANBAXY FY 2010 PAT AT $327 Mn (Rs. 14968 Mn), UP ON STRONG EARNINGS - Board Recommends Dividend of 40 Percent".

Ranbaxy Laboratories Limited has informed the Exchange that the Board of Directors of the Company at its meeting held on February 22, 2011 has recommended Dividend of Rs.2 per equity share for the year ended December 31, 2010, for approval of the shareholders at the ensuing Annual General Meeting. Post approval of the shareholders, the dividend will be paid on May 16, 2011.

Ranbaxy Laboratories Limited has informed the Exchange regarding the standalone Results for the year ended on 31-DEC-2010 as follows: Net Sales of Rs. 525148.6 lacs for year ending on 31-DEC-2010 against Rs. 452118 lacs for the year ending on 31-DEC-2009. Net Profit / (Loss) of Rs. 114872.6 lacs for the year ending on 31-DEC-2010 against Rs. 57198.4 lacs for the year ending on 31-DEC-2009.

Ranbaxy Laboratories Limited has submitted to the Exchange the Standalone and Consolidated Financial Results for the period ended December 31,2010.

Ranbaxy Laboratories Limited has informed the Exchange regarding the consolidated Results for the year ended on 31-DEC-2010 as follows: Net Sales of Rs. 853545 lacs for year ending on 31-DEC-2010 against Rs. 732940.3 lacs for the year ending on 31-DEC-2009. Net Profit / (Loss) of Rs. 149675.1 lacs for the year ending on 31-DEC-2010 against Rs. 29649.2 lacs for the year ending on 31-DEC-2009.

Ranbaxy Laboratories Limited has informed the Exchange regarding a press release dated January 31, 2011, titled "Ranbaxy and The Government of Yaroslavl Region, Russia, sign MOU for cooperation in the field of Healthcare and Medical Science".

Ranbaxy Laboratories Limited has informed the Exchange that Mr. Omesh Sethi, President & Chief Financial Officer has resigned from the services of the Company, with effect from January 25, 2011.

Ranbaxy Laboratories Limited has informed the Exchange that the ESOPs Allotment Committee of Directors vide Resolution by Circulation passed on January 11, 2011, allotted 211,615 Equity Shares on exercise of stock options under the Employees Stock Option Scheme(s) of the Company. The paid-up Equity Share Capital of the Company post allotment is 421,252,308 Equity Shares of Rs.5 each aggregating Rs.2,106,261,540/-.

Ranbaxy Laboratories Limited has informed the Exchange that the Registered office of the Company will shift within the city of Mohali effective January 1, 2011. The new address of the Registered Office is as under : Ranbaxy Laboratories Limited, A-41, Industrial Area Phase VIII-A, Sahibzada Ajit Singh Nagar, Mohali - 160 071 (Punjab).

Ranbaxy Laboratories Limited has informed the Exchange regarding a press release dated December 20, 2010, titled "Sonke, a Black Empowered Pharmaceutical Company, to play significant role in fight against HIV AIDS, in South Africa Wins 21.9% of Government Tender".

Ranbaxy Laboratories Limited has informed the Exchange regarding a press release dated November 30, 2010, titled "Ranbaxy launches Donepezil 5 MG and 10 MG tablets to U.S. Healthcare System".

Ranbaxy Laboratories Limited has informed the Exchange regarding a press release dated November 11, 2010, titled "Ranbaxy delivers continued growth in Sales and PAT for Q3, 2010".

Ranbaxy Laboratories Limited has submitted to the Exchange the Standalone and Consolidated Financial Results for the period ended September 30,2010.

Ranbaxy Laboratories Limited has informed the Exchange regarding the consolidated Results for the quarter ended on 30-SEP-2010 as follows: Net Sales of Rs. 188378.2 lacs for quarter ending on 30-SEP-2010. Net Profit / (Loss) of Rs. 30793.6 lacs for the quarter ending on 30-SEP-2010.

Ranbaxy Laboratories Limited has informed the Exchange regarding the standalone Results for the quarter ended on 30-SEP-2010 as follows: Net Sales of Rs. 113098.9 lacs for quarter ending on 30-SEP-2010 against Rs. 118960.4 lacs for the quarter ending on 30-SEP-2009. Net Profit / (Loss) of Rs. 22176.9 lacs for the quarter ending on 30-SEP-2010 against Rs. 18608.1 lacs for the quarter ending on 30-SEP-2009.

Ranbaxy Laboratories Limited has informed the Exchange that the ESOPs Allotment Committee of Directors vide Resolution by Circulation passed on October 08,2010 allotted 286,536 Equity Shares on exercise of stock options under the Employees Stock Option Scheme(s) of the Company. The paid-up Equity Share Capital of the Company post allotment is 421,040,693 Equity Shares of Rs. 5 each aggregating Rs. 2,105,203,465/-.

Ranbaxy Laboratories Limited has informed the Exchange regarding a press release dated September 1, 2010, titled ''Ranbaxy sets up new manufacturing facility in South Africa''.

Ranbaxy Laboratories Limited has informed the Exchange that Mr. Arun Sawhney has assumed the office of the Managing Director of the Company on August 20, 2010

Ranbaxy Laboratories Limited has informed the Exchange regarding a press release dated August 12, 2010, titled ''Ranbaxy Board announces Change in Executive Leadership''.

Ranbaxy Laboratories Limited has informed the Exchange regarding a press release dated August 12, 2010, titled ''Ranbaxy achieves USD 1 Billion revenue and USD 282 mn PAT for H1'2010 - after record Q1 sales, Q2 growth at 22%''.

Ranbaxy Laboratories Limited has informed the Exchange that at the Board meeting of the Company held on August 12, 2010 :(a). Mr. Atul Sobti has stepped down from the position of CEO & Managing Director of the Company effective August 19, 2010; and (b).Mr. Arun Sawhney, currently President - Global Pharmaceutical Business of the Company has been appointed as Managing Director of the Company for a period of three years effective August 20, 2010, subject to the approval of the shareholders.

Ranbaxy Laboratories Limited has informed the Exchange regarding the consolidated Results for the quarter ended on 30-JUN-2010 as follows: Net Sales of Rs. 209878.1 lacs for quarter ending on 30-JUN-2010. Net Profit / (Loss) of Rs. 32571.4 lacs for the quarter ending on 30-JUN-2010.

Ranbaxy Laboratories Limited has informed the Exchange regarding the standalone Results for the quarter ended on 30-JUN-2010 as follows: Net Sales of Rs. 106958 lacs for quarter ending on 30-JUN-2010 against Rs. 100647.3 lacs for the quarter ending on 30-JUN-2009. Net Profit / (Loss) of Rs. (7.7) lacs for the quarter ending on 30-JUN-2010 against Rs. 67545 lacs for the quarter ending on 30-JUN-2009.

Ranbaxy Laboratories Limited has informed the Exchange regarding a press release dated July 21, 2010, titled ''Daiichi Sankyo to Leverage Ranbaxy's Network to Market its Innovative Antibiotic Tavanic (Levofloxacin) in Romania and South Africa''.

Ranbaxy Laboratories Limited has informed the Exchange that the ESOPs Allotment Committee of Directors vide Resolution by Circulation passed on July 12, 2010, allotted 85,955 Equity Shares on exercise of stock options under the Employees Stock Option Scheme(s) of the Company. The paid-up Equity Share Capital of the Company post allotment is 420,754,157 Equity Shares of Rs. 5 each aggregating Rs. 2,103,770,785/-.

Ranbaxy Laboratories Limited has informed the Exchange regarding a press release dated July 02, 2010, titled ''Daiichi Sankyo and Ranbaxy to Integrate New Drug Research and Development System''.

Ranbaxy Laboratories Limited has informed the Exchange regarding a press release dated June 10, 2010, titled "Ranbaxy Launches Antiplatelet Agent Prasugrel in India".

Ranbaxy Laboratories Limited has informed the Exchange regarding a Press Release dated June 8, 2010 titled "Ranbaxy launches Generic Atorvastatin, 'Lipogen', a cholestrol-reducing medication in South Africa".

Ranbaxy Laboratories Limited has informed the Exchange regarding a press release dated May 21, 2010, titled "Ranbaxy launches Atorvastatin, cholesterol-reducing medication into the Canadian Healthcare System".

Ranbaxy Laboratories Limited has informed the Exchange regarding a press release dated May 11, 2010 , titled "Ranbaxy delivers quarterly sales of over USD 500 MN for the first time, records profit after tax of USD 210 MN".

Ranbaxy Laboratories Limited has informed the Exchange regarding the standalone Results for the quarter ended on 31-MAR-2010 as follows: Net Sales of Rs. 164851.4 lacs for quarter ending on 31-MAR-2010 against Rs. 80222.1 lacs for the quarter ending on 31-MAR-2009. Net Profit / (Loss) of Rs. 87180.2 lacs for the quarter ending on 31-MAR-2010 against Rs. (77777.8) lacs for the quarter ending on 31-MAR-2009.

Ranbaxy Laboratories Limited has informed the Exchange regarding the consolidated Results for the quarter ended on 31-MAR-2010 as follows: Net Sales of Rs. 248674.9 lacs for quarter ending on 31-MAR-2010. Net Profit / (Loss) of Rs. 96058.4 lacs for the quarter ending on 31-MAR-2010.

Ranbaxy Laboratories Limited has informed the Exchange that the Members of the Company at the Annual General Meeting (AGM) held today i.e. May 10, 2010, have unanimously approved : (1) Adoption of audited profit & loss Account for the year ended December 31, 2009 and the Balance Sheet as at that date and the Reports of the Directors and the Auditors thereon; (2) Appointment of M/s B S R & Co as Auditors of the Company to hold office upto the conclusion of the next AGM and authorized the Board of Directors and Committee thereof to fix their remuneration; (3) Appointment of Dr. Tsutomu Une as a

Ranbaxy Laboratories Ltd has informed the Exchange that : "The Company had allotted 23,834,333 Warrants on October 20, 2008 on preferential basis to Daiichi Sankyo Company, Limited (Daiichi Sankyo), each warrant exercisable into one Equity Share at a price of Rs.737 per share at any time between 6 months to 18 months from the date of allotment of warrants and that the Company had received Rs.73.70 per warrant from Daiichi Sankyo, being 10% of the exercise price. In this regard, we wish to inform you that Daiichi Sankyo has not opted to exercise aforesaid warrants into shares. Hence as per the

Ranbaxy Laboratories Ltd has submitted to the Exchange a copy of the notice of Annual General Meeting of the Company to be held on May 10, 2010. A copy of the same shall be available on the NSE website (http://www.nseindia.com) under: Corporates > Latest Announcements and on the Extranet Server (/Common/CorporateAnnouncements).<a href=/content/corporate/Ranbaxy_AGMNot_19042010.zip target=NEW> For more details click here.</a>

Ranbaxy Laboratories Ltd has informed the Exchange that the ESOPs Allotment Committee of Directors vide Resolution by Circulation Passed on April 13, 2010, allotted 144,956 Equity Shares on exercise of stock options under the Employees Stock Option Scheme(s) of the Company. The paid-up Equity Share Capital of the Company post allotment is 420,668,202 Equity Shares of Rs. 5 each aggregating Rs.2,103,341,010/-.

Ranbaxy Laboratories Ltd has informed the Exchange regarding a press release dated March 29, 2010, titled "Ranbaxy and pfenex Announce Collaboration for the Development of a Biosimilar Therapeutic Protein". A copy of the press release shall be available on the NSE website http://www.nseindia.com) under: Corporates > Latest announcements and on the Extranet Server (/Common/Corporate Announcements).<a href=/content/corporate/ranbaxy_pr_29032010.zip target=NEW> For more details click here.</a>

Ranbaxy Laboratories Ltd has informed the Exchange that the Annual General Meeting of the Company has been fixed for May 10, 2010 and share transfer books for this purpose will remain closed from May 03, 2010 to May 10, 2010 (both days inclusive).

Ranbaxy Laboratories Ltd has informed the Exchange regarding a press release dated March 15, 2010, titled "Ranbaxy announces settlement of ACTOS� (Pioglitazone Hydrochloride) Patent Litigation." A copy of the press release shall be available on the NSE website http://www.nseindia.com) under: Corporates > Latest announcements and on the Extranet Server (/Common/Corporate Announcements).<a href=/content/corporate/Ranbaxy_PR_15032010.zip target=NEW> For more details click here.</a>

Ranbaxy Laboratories Ltd has informed the Exchange that the Company has formulated its Medium Term Plan (MTP) for the period 2010-2012. As per the MTP, the Company aims to achieve global consolidated turnover of Three Billion US Dollars (approx. INR 140 billion) for the financial year ending December 2012.<a href=/content/corporate/Ranbaxy_Updt_12032010.zip target=NEW> For more details click here.</a>